Stay updated on Brentuximab & Nivolumab for Early Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab & Nivolumab for Early Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Brentuximab & Nivolumab for Early Hodgkin Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdditions include UI labels Show glossary and Hide glossary, plus policy/version text: Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Deletions include Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.SummaryDifference0.2%

- Check21 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no substantive changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check50 days agoChange DetectedA centralized Locations section has been added listing all study sites by state (Alabama, California, Georgia, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Texas, Utah). Removed individual state location subsections and applied revision v3.3.3.SummaryDifference1%

- Check72 days agoChange DetectedPublications section now states entries are automatically filled from PubMed, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check79 days agoChange DetectedNotice banner about government funding status was removed from the page, which does not affect the study details or core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check101 days agoChange DetectedNo additions or deletions detected on the Study Details page for NCT03712202; the trial objectives, eligibility criteria, and listed locations remain as published.SummaryDifference0.3%

Stay in the know with updates to Brentuximab & Nivolumab for Early Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab & Nivolumab for Early Hodgkin Lymphoma Clinical Trial page.